AU1675083A - Hepatitis B virus vaccine - Google Patents

Hepatitis B virus vaccine

Info

Publication number
AU1675083A
AU1675083A AU16750/83A AU1675083A AU1675083A AU 1675083 A AU1675083 A AU 1675083A AU 16750/83 A AU16750/83 A AU 16750/83A AU 1675083 A AU1675083 A AU 1675083A AU 1675083 A AU1675083 A AU 1675083A
Authority
AU
Australia
Prior art keywords
hepatitis
virus vaccine
yeast
hbsag
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU16750/83A
Other versions
AU584580B2 (en
Inventor
Theresa Cabezon
Marjolene Crabeel
Nigel Harford
Michel De Wilde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline RIT
Original Assignee
SmithKline RIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline RIT filed Critical SmithKline RIT
Publication of AU1675083A publication Critical patent/AU1675083A/en
Application granted granted Critical
Publication of AU584580B2 publication Critical patent/AU584580B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A DNA fragment capable of coding for HBsAg and DNA derivatives of Dane particles is fused to the region for controlling the arg3 gene of yeast and cloned in a yeast vector. The recombinant vector is employed for transforming the competent yeast cells in which the HBsAg gene is expressed.
AU16750/83A 1982-09-08 1983-07-12 Hepatitis B virus vaccine Ceased AU584580B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41578982A 1982-09-08 1982-09-08
US415789 1987-09-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU15692/88A Division AU1569288A (en) 1982-09-08 1988-05-06 Hepatitis b virus vaccine
AU31318/89A Division AU3131889A (en) 1982-09-08 1989-03-14 Hepatitis b virus vaccine

Publications (2)

Publication Number Publication Date
AU1675083A true AU1675083A (en) 1984-03-15
AU584580B2 AU584580B2 (en) 1989-06-01

Family

ID=23647197

Family Applications (4)

Application Number Title Priority Date Filing Date
AU16750/83A Ceased AU584580B2 (en) 1982-09-08 1983-07-12 Hepatitis B virus vaccine
AU15692/88A Abandoned AU1569288A (en) 1982-09-08 1988-05-06 Hepatitis b virus vaccine
AU31318/89A Abandoned AU3131889A (en) 1982-09-08 1989-03-14 Hepatitis b virus vaccine
AU90014/91A Abandoned AU9001491A (en) 1982-09-08 1991-12-24 Hepatitis b virus vaccine

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU15692/88A Abandoned AU1569288A (en) 1982-09-08 1988-05-06 Hepatitis b virus vaccine
AU31318/89A Abandoned AU3131889A (en) 1982-09-08 1989-03-14 Hepatitis b virus vaccine
AU90014/91A Abandoned AU9001491A (en) 1982-09-08 1991-12-24 Hepatitis b virus vaccine

Country Status (22)

Country Link
EP (1) EP0106828B1 (en)
JP (5) JPS5971694A (en)
KR (1) KR840006014A (en)
AT (1) ATE91718T1 (en)
AU (4) AU584580B2 (en)
CA (1) CA1222707A (en)
CY (1) CY1932A (en)
DE (1) DE3382704T2 (en)
DK (1) DK406483A (en)
ES (4) ES525439A0 (en)
FI (1) FI833205A (en)
GR (1) GR78982B (en)
HK (1) HK1004570A1 (en)
HU (1) HU196625B (en)
IE (1) IE60387B1 (en)
IL (1) IL69202A (en)
MA (1) MA19895A1 (en)
MY (1) MY102920A (en)
NO (1) NO833198L (en)
NZ (1) NZ204952A (en)
PT (1) PT77265B (en)
ZA (1) ZA836658B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608813B2 (en) * 1987-03-09 1991-04-18 Merck & Co., Inc. Purification of recombinant hepatitis b surface antigen
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936699A (en) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst Shuttle vector
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
WO1986001534A1 (en) * 1984-09-04 1986-03-13 Takeda Chemical Industries, Ltd. Recombinant dna and its use
WO1986003411A1 (en) * 1984-12-12 1986-06-19 Takeda Chemical Industries, Ltd. Process for preparing novel protein
WO1986007384A1 (en) * 1985-06-03 1986-12-18 Takeda Chemical Industries, Ltd. Process for preparing hapatitis b virus surface antigen p31
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
DE3677851D1 (en) * 1985-08-05 1991-04-11 Merck & Co Inc METHOD FOR INCREASING THE PRODUCTION OF RECOMBINANT PROTEIN IN YEARS OF THE GENERATION SACCHAROMYCES.
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) * 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
US4962656A (en) * 1989-06-30 1990-10-16 The United States Of America As Represented By The United States Department Of Energy Control and monitoring method and system for electromagnetic forming process
TW340132B (en) * 1994-10-20 1998-09-11 Ibm Structure for use as an electrical interconnection means and process for preparing the same
JP4028850B2 (en) * 2004-02-04 2007-12-26 株式会社名機製作所 Mold for molding disk substrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES487106A0 (en) * 1978-12-22 1981-05-16 Biogen Nv A METHOD FOR PRODUCING AT LEAST ONE POLYPEPTIDE SHOWING HBV ANTIGENICITY
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (en) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608813B2 (en) * 1987-03-09 1991-04-18 Merck & Co., Inc. Purification of recombinant hepatitis b surface antigen
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof

Also Published As

Publication number Publication date
ES8600938A1 (en) 1985-10-16
IE60387B1 (en) 1994-07-13
EP0106828A2 (en) 1984-04-25
IL69202A (en) 1991-08-16
ES532730A0 (en) 1985-10-16
MY102920A (en) 1993-03-31
ES8600939A1 (en) 1985-10-16
DE3382704T2 (en) 1994-02-10
EP0106828B1 (en) 1993-07-21
FI833205A0 (en) 1983-09-07
DK406483D0 (en) 1983-09-07
ES532732A0 (en) 1985-10-16
AU9001491A (en) 1992-02-27
DK406483A (en) 1984-03-09
CA1222707A (en) 1987-06-09
JP2702899B2 (en) 1998-01-26
EP0106828A3 (en) 1985-11-21
CY1932A (en) 1983-09-06
AU1569288A (en) 1988-07-28
PT77265A (en) 1983-09-01
AU584580B2 (en) 1989-06-01
AU3131889A (en) 1989-07-20
JPH02231084A (en) 1990-09-13
DE3382704D1 (en) 1993-08-26
KR840006014A (en) 1984-11-21
ATE91718T1 (en) 1993-08-15
PT77265B (en) 1986-02-04
JPH02464A (en) 1990-01-05
ES8506350A1 (en) 1985-07-01
HU196625B (en) 1988-12-28
NZ204952A (en) 1986-05-09
JP2522825B2 (en) 1996-08-07
ZA836658B (en) 1984-06-27
ES525439A0 (en) 1985-07-01
HK1004570A1 (en) 1998-11-27
GR78982B (en) 1984-10-02
IE832099L (en) 1984-03-08
JPS5971694A (en) 1984-04-23
ES532731A0 (en) 1985-11-01
ES8602120A1 (en) 1985-11-01
NO833198L (en) 1984-03-09
JPH08317796A (en) 1996-12-03
MA19895A1 (en) 1984-04-01
FI833205A (en) 1984-03-09
JPH02116A (en) 1990-01-05

Similar Documents

Publication Publication Date Title
AU584580B2 (en) Hepatitis B virus vaccine
EP0291586A3 (en) Recombinant hepatitis b surface antigen and vaccine containing it
IE800991L (en) HBs Ag GENE AND PRODUCT
DE3280284D1 (en) MANUFACTURE OF SURFACE HEPATITIS B ANTIGES IN YEAST.
IL69423A0 (en) Recombinant plasmid inserted with hepatitis b virus gene,yeast transformed with said recombinant plasmid and production of hepatitis b virus surface antigen
EP0171908A3 (en) Hepatitis b virus surface antigen and production thereof
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
ZA893440B (en) Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
EP0037723A3 (en) Expression of hormone genomic clones
EP0216564A3 (en) Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0152030A3 (en) Adult t cell leukemia virus antigen polypeptide
CA2002862A1 (en) Cloning and expression of a protein which modulates cellular response to type i interferon
ES8602935A1 (en) Shuttle vector
JPS6467191A (en) Recombinant dna plasmid having integrated hepatitis b virus gene, transformed animal cell, hepatitis b viral surface antigen protein and production thereof
RU1651555C (en) Recombinant plasmid dna p7, 5c coding antigen hepatitis b virus
SU1380209A1 (en) RECOMBINANT PLASMID DNA PUR 291-HAV 22 ENCODING SYNTHESIS OF HYBRID POLYPEPTIDE OF HEPATITIS VIRUS A ANTIGENIC DETERMINANTS WITH β-GALACTOSIDASE
ATE53235T1 (en) SYNTHESIS OF HUMAN VIRAL ANTIGENS USING YEAST.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired